Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Urology Cancer Center and GU Research Network | Researchclopedia

Back to institutions

Urology Cancer Center and GU Research Network

Omaha, Nebraskahealthcare

81

Works

705

Citations

16

h-index

Top Research Topics

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Cancer Immunotherapy and Biomarkers

Top Researchers

Luke T. Nordquist RCA (United States)

176 works5,507 citationsh-index: 22

Recent Research

2542eTiP Phase I/II dose escalation and expansion of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC): The ARTISAN trial

O. Sartor,J.S. de Bono,et al.

20250 citations

Medical Imaging Techniques and Applications

Immunotherapy and Immune Responses

Cancer Treatment and Pharmacology

Prostate Cancer Diagnosis and Treatment

PARP inhibition in cancer therapy

Cancer, Lipids, and Metabolism

Advanced Breast Cancer Therapies

Bladder and Urothelial Cancer Treatments

RNA Interference and Gene Delivery

Sudhir Isharwal Oregon Health & Science University

77 works794 citationsh-index: 16

Matthew McDonald

15 works215 citationsh-index: 7

5 works16 citationsh-index: 2

L. Nordquist Urology Cancer Center and GU Research Network

3 works0 citationsh-index: 0

Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with advanced solid tumors: Results from two dose-escalation cohorts of the phase 1b STELLAR 002 study.

Benjamin Garmezy,Bert O'Neil,et al.

20250 citations

Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore

Karim Fizazi,Michael J. Morris,et al.

20250 citations

Efficacy of <sup>177</sup> Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis.

Omid Yazdanpanah,Jérémie Calais,et al.

20255 citations

1641P Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects

Christos E. Kyriakopoulos,Gurkamal Chatta,et al.

20243 citations

1599P Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore

K. Fizazi,M.J. Morris,et al.

20242 citations